Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Philogen SpA (DE:78Q)
STUTTGART:78Q
Holding DE:78Q?
Track your performance easily
78Q Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€16.25 - €22.00
Previous Close€19.55
Volume100.00
Average Volume (3M)300.00
Market Cap
€581.93M
Enterprise Value€507.62M
Total Cash (Recent Filing)€86.20M
Total Debt (Recent Filing)€11.89M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Nov 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume300
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.00Price Target Upside27.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialFinal data from the P3 trial of neoadjuvant Nidlegy in locally advanced resectable melanoma confirm the superiority of Nidlegy vs. surgery alone.
Financial ForecastsTaking into account the expanded laBCC population, peak sales for Nidlegy in NMSC are now projected to reach €1.8bn, reflecting a significant upward revision from previous estimates.
Strategic PartnershipsPreparations for commercialisation are underway with partner Sun Pharma, enhancing the market reach and support for Nidlegy post-approval.
Bears Say
Drug Safety ConcernsPatients in the Nidlegy arm experienced more treatment-related adverse events.
Financial HealthPhilogen’s net cash position has decreased by 9.4%.
Product Launch DelaysFollowing the announced strategic change in the development of Nidlegy in NMSC, there is an expected delay in laSCC launch and a two-year delay in laBCC launch.
---
Options Prices
Currently, No data available
---
Ownership Overview
78Q FAQ
What was Philogen SpA’s price range in the past 12 months?
Philogen SpA lowest stock price was €16.25 and its highest was €22.00 in the past 12 months.
What is Philogen SpA’s market cap?
Currently, no data Available
When is Philogen SpA’s upcoming earnings report date?
Philogen SpA’s upcoming earnings report date is Nov 07, 2024 which is in 27 days.
How were Philogen SpA’s earnings last quarter?
Philogen SpA released its earnings results on Sep 25, 2024. The company reported -€0.39 earnings per share for the quarter, missing the consensus estimate of -€0.32 by -€0.07.
Is Philogen SpA overvalued?
According to Wall Street analysts Philogen SpA’s price is currently Undervalued.
Does Philogen SpA pay dividends?
Philogen SpA does not currently pay dividends.
What is Philogen SpA’s EPS estimate?
Philogen SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Philogen SpA have?
Philogen SpA has 29,242,860 shares outstanding.
What happened to Philogen SpA’s price movement after its last earnings report?
Philogen SpA reported an EPS of -€0.39 in its last earnings report, missing expectations of -€0.32. Following the earnings report the stock price went down -0.254%.
Which hedge fund is a major shareholder of Philogen SpA?
Currently, no hedge funds are holding shares in DE:78Q
---
Philogen SpA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.20%
12-Months-Change
Fundamentals
Return on Equity
-32.49%
Trailing 12-Months
Asset Growth
-22.33%
Trailing 12-Months
Company Description
Philogen SpA
Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others.
---
78Q Stock 12 Month Forecast
Average Price Target
€25.00
▲(27.88% Upside)
Technical Analysis
Best Analysts Covering 78Q
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+15.40%
reiterated a buy rating 6 months ago
Copying Rajan Sharma's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.40% per trade.
---